F1052V - Question about Pipeline drug classification


New member

My son has F1052V and (the doctors agree) a duplication/deleation mutation that he has not been tested for yet (they did not test for these in his sequencing). My question is, does anyone know which group of mutations (F1052V) would fall under for the new drugs coming on the pipeline? I was under the impression that we would have to wait until they target F1052V (because the deleation/duplication will be even more rare) but was told by a wondeful retired CF doctor that he might fall into one of the groups that will have treatments? Does anyone have any idea?

Thank you!!